Alignment Healthcare, Inc.

ALHC

CIK 0001832466 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$1.01B
↑+44.4% +$312Mvs FY2024 (Q4)
Operating Income
$879M
↑+48.4% +$287Mvs FY2024 (Q4)
Net Income
$875M
↑+49.1% +$288Mvs FY2024 (Q4)
Gross Profit
$1.01B
↑+44.4% +$312Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
62/100
  • Profitability
    0ROIC 2.5% (10% = solid, 20%+ = moat)
  • Liquidity
    60Current Ratio 1.71 (above 1.5 = solid)
  • Leverage
    10D/E 1.80 (under 0.5 = conservative)
  • Efficiency
    100Asset Turnover 4.27x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +44.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 0.8% · trend +4.8pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project ALHC's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$9.83
Total enterprise IV
$1.95B
Diluted shares
0.20B
Terminal PV
$1.41B (72% of total)
Year-5 FCF
$166M
YearProjected FCFDiscounted PV
+1$122M$111M
+2$132M$109M
+3$143M$107M
+4$154M$105M
+5$166M$103M
Terminal$2.27B$1.41B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$27M
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$62M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$1.07B
everything owned
Total liabilities
$887M
everything owed
Stockholders' equity
$179M
shareholder claim
Net debt
$-253M
Net cash position ($253M)

Recent performance · 25 quarters

Revenue↑+44.4% +$312M
$1.01B
Net Income↑+114.1% +$30M
$4M
Free Cash Flow↑+45.8% +$4M
$-5M
Operating Margin↑+3.6pts
0.8%

Drill down